Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

1,060.86
452,590

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $1,060.80 -0.06 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose

Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.

    Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact

    Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.

      Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

      We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

        Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

        After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

          Regeneron Presents Positive Phase II Data on HoFH Candidate

          Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.

            The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

            The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

              Theravance/Mylan Presents Phase III Data on COPD Candidate

              Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).

                Arpita Dutt headshot

                Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data

                Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.

                  Merck Presents Phase II Data on Chronic Cough Candidate

                  Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.

                    Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                      Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose

                      Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.

                        Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session

                        Compugen Ltd. (CGEN) shares rose over 10% in the last trading session.

                          Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day

                          Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

                            Quite a few deals were announced this week including by companies like Biogen (BIIB).

                              Kevin Cook headshot

                              Bull of the Day: Regeneron (REGN)

                              Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

                                TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1

                                TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.

                                  Brian Hamilton headshot

                                  Bear of the Day: AMAG Pharmaceuticals (AMAG)

                                  Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.

                                    Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up

                                    Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.

                                      Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite

                                      Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.

                                        STERIS (STE) Grapples with Headwinds: Should You Dump?

                                        On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.

                                          Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                                          Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                                            Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                                            Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.

                                              Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

                                              On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

                                                Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

                                                Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

                                                  Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.